Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention

JACC: Cardiovascular Interventions

Volumn 1, Issue 2, 2008, Pages 111-121

  Kereiakes, Dean J ^a   Gurbel, Paul A ^b  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

^b SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; HYPERICUM PERFORATUM EXTRACT; PLACEBO; PRASUGREL; PROTEINASE ACTIVATED RECEPTOR 1 BLOCKING AGENT; RIFAMPICIN; SCH 530348; THIENOPYRIDINE DERIVATIVE; THROMBIN INHIBITOR; TICAGRELOR; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; WARFARIN;

ADJUVANT THERAPY; ADVERSE OUTCOME; ANTICOAGULANT THERAPY; ARTERY INJURY; BLEEDING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; CORONARY STENT; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; PERIOPERATIVE PERIOD; POSTOPERATIVE THROMBOSIS; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBUS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ASPIRIN; CORONARY ARTERY DISEASE; DRUG RESISTANCE; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; RISK FACTORS; THROMBIN; TICLOPIDINE; TREATMENT OUTCOME;

EID: 41949099615     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2008.01.005     Document Type: Review

References (109)

1. Wilentz J.R., Sanborn T.A., Haudenschild C., et al. Platelet accumulation in experimental angioplasty: time course in relation to vascular injury. Circulation 75 (1987) 636-642
2. Nelken N.A., Soifer S.J., Okeff J., et al. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 90 (1992) 1614-1621
3. Ruggeri Z.M. Platelets in atherothrombosis. Nat Med 8 (2002) 1227-1234
4. Gurbel P.A., Bliden K.P., Hayes K.M., and Tantry U. Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther 2 (2004) 535-545
5. Gurbel P.A., and Tantry U. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor. Rev Cardiovasc Med 7 (2006) S20-S28
6. Tantry U.S., Etherington A., Bliden K.P., and Gurbel P.A. Antiplatelet therapy: current strategies and future trends. Future Cardiol 2 (2006) 343-366
7. Peltonen S., Lassila R., and Heikkila J. Activation of coagulation and fibrinolysis despite heparinization during successful elective coronary angioplasty. Thromb Res 82 (1996) 459-468
8. Gregorini L., Marco J., Fajadet J., et al. Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures. J Am Coll Cardiol 29 (1997) 13-20
9. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 330 (1994) 956-961
10. Lincoff A.M., Popma J.J., Ellis S.G., et al. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol 19 (1992) 926-935
11. Kabbani S.S., Watkins M.W., Ashikaga T., Terrien E.F., Sobel B.E., and Schneider D.J. Usefulness of platelet reactivity before percutaneous coronary intervention in determining cardiac risk one year later. Am J Cardiol 91 (2003) 876-878
12. Frossard M., Fuchs I., Leitner J.M., et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 110 (2004) 1392-1397
13. Neumann E.J., Gawaz M., Ott I., May A., Mossmer G., and Schomig A. Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. J Am Coll Cardiol 27 (1996) 15-21
14. Huczek Z., Kochman J., Filipiak K.J., et al. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol 46 (2005) 284-290
15. Campo G., Valgimigli M., Gemmati D., et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY study. J Am Coll Cardiol 48 (2006) 2178-2185
16. Soffer D., Moussa I., Karatepe M., et al. Suboptimal inhibition of platelet aggregation following tirofiban bolus in patients undergoing percutaneous coronary intervention for unstable angina pectoris. Am J Cardiol 91 (2003) 872-875
17. Gurbel P.A., Bliden K.P., Hiatt B.L., and O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913
18. Chakhtoura E.Y., Shamoon F.E., Haft J.I., Obiedzinski G.R., Cohen A.J., and Watson R.M. Comparison of platelet activation in unstable and stable angina pectoris and correlation with coronary angiographic findings. Am J Cardiol 86 (2000) 835-839
19. Ault K.A., Cannon C.P., Mitchell J., et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 33 (1999) 634-639
20. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54 (2005) 2430-2435
21. Miyamoto S., Kawano H., Kudoh T., et al. Usefulness of preprocedural platelet aggregation to predict restenosis after percutaneous coronary intervention. Am J Cardiol 96 (2005) 71-73
22. Steinhubl S.R., Talley J.D., Braden G.A., et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 103 (2001) 2572-2578
23. IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 349 (1997) 1422-1428
24. RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 96 (1997) 1445-1453
25. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet 356 (2000) 2037-2044
26. Topol E.J., Moliterno D.J., Herrmann H.C., et al., TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 344 (2001) 1888-1894
27. Hermann H.C., Swierkosz T.A., Kapoor S., et al. Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol 89 (2002) 1293-1297
28. Kereiakes D.J., and Goldschmidt-Clermont P. Platelet glycoprotein IIb/IIIa inhibitors: effects beyond the platelet. In: Lincoff A.M. (Ed). Contemporary Cardiology: Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. 2nd edition (2003), Humana Press, Totowa, NJ
29. Kleiman N.S., Grazeiadei N., Maresh K., et al. Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions. Am Heart J 140 (2000) 492-501
30. Dalby M., Montalescot G., Bal dit Sollier C., et al. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. J Am Coll Cardiol 43 (2004) 162-168
31. Gurbel P.A., Bliden K.P., Zaman K.A., Yoho J.A., Hayes K.M., and Tantry U.S. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 111 (2005) 1153-1159
32. Chan A.W., Moliterno D.J., Berger P.B., et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoPro Give Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol 42 (2003) 1188-1195
33. Gurbel P.A., Bliden K.P., and Tantry U.S. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. J Am Coll Cardiol 48 (2006) 2186-2191
34. Bonz A.W., Lengenfelder B., Strotmann J., et al. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary intervention after pretreatment with aspirin and clopidogrel (TOPSTAR trial). J Am Coll Cardiol 40 (2002) 662-668
35. Tcheng J.E., and Campbell M.E. Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition?. J Am Coll Cardiol 42 (2003) 1196-1198
36. Kastrati A., Mehilli J., Neumann F.J., et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295 (2006) 1531-1538
37. Ndrepepa G., Kastrati A., Mehilli J., et al. Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions. Circulation 114 (2006) 2040-2046
38. Kastrati A., Mehilli J., Schuhlen H., et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 350 (2004) 232-238
39. Matetzky S., Shenkman B., Guetta V., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
40. Gurbel P.A., Bliden K.P., Guyer K., et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 46 (2005) 1820-1826
41. Gurbel P.A., Bliden K.P., Samara W., et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 46 (2005) 1827-1832
42. Hochholzer W., Trenk D., Bestehorn H.P., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48 (2006) 1742-1750
43. Buonamici P., Marcucci R., Migliorini A., et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 49 (2007) 2312-2317
44. Price M.J., Valencia R., Gollapudi R.R., et al. The response to clopidogrel measured by a point-of-care assay following percutaneous coronary intervention is associated with stent thrombosis over 6 month follow-up. J Am Coll Cardiol 49 Suppl B (2007) 13B (abstr)
45. Bliden K.P., DiChiara J., Tantry U.S., Bassi A.K., Chaganti S.K., and Gurbel P.A. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?. J Am Coll Cardiol 49 (2007) 657-666
46. Gurbel P.A., Becker R.C., Mann K.G., Steinhubl S.R., and Michelson A.D. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 50 (2007) 1822-1834
47. Awtry E.H., and Loscalzo J. Aspirin. Circulation 101 (2000) 1206-1218
48. Patrono C., Coller B., Dalen J.E., et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 117 (2001) 39S-63S
49. Bhatt D.L. Aspirin resistance: more than just a laboratory curiosity. J Am Coll Cardiol 43 (2004) 1127-1129
50. Hovens M.M., Snoep J.D., Eikenboom J.C., van der Bom J.G., Mertens B.J., and Huisman M.V. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 153 (2007) 175-181
51. Tantry U.S., Bliden K.P., and Gurbel P.A. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 46 (2005) 1705-1709
52. Gurbel P.A., Bliden K.P., DiChiara J., et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 115 (2007) 3156-3164
53. Peters R.J., Mehta S.K., Fox K.A., et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 108 (2003) 1682-1687
54. Serebruany V.L., Steinhubl S.R., Berger P.B., et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 95 (2005) 1218-1222
55. Chen W.H., Lee P.Y., Ng W., Tse H.F., and Lau C.P. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43 (2004) 1122-1126
56. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
57. Wenaweser P., Dorffler-Melly J., Imboden K., et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 45 (2005) 1748-1752
58. Lev E.I., Patel R.T., Maresh K.J., et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47 (2006) 27-33
59. Dichiara J., Bliden K.P., Tantry U.S., et al. Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients. Platelets 18 (2007) 414-423
60. Quinn M.J., and Fitzgerald D.J. Ticlopidine and clopidogrel. Circulation 100 (1999) 1667-1672
61. Neumann F., Gawaz M., Dickfield T., et al. Antiplatelet effect of ticlopidine after coronary stenting. J Am Coll Cardiol 29 (1997) 1515-1519
62. Leon M.B., Baim D.S., Popma J.J., et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restonsis Study Investigators. N Engl J Med 339 (1998) 1665-1671
63. Schomig A., Neumann F.J., Kastrati A., et al. : A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med 334 (1996) 1084-1089
64. Bertrand M.E., Rupprecht H.-J., Urban P., Gershlick A.H., and CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 102 (2000) 624-629
65. Lau W.C., Gurbel P.A., Watkins P.B., et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109 (2004) 166-171
66. O'Donoghue M., and Wiviott S.D. Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?. Circulation 114 (2006) e600-e606
67. Gurbel P.A., and Tantry U.S. Clopidogrel resistance?. Thromb Res 120 (2007) 311-321
68. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 26 (2006) 1895-1900
69. Samara W.M., Bliden K.P., Tantry U.S., and Gurbel P.A. The difference between clopidogrel responsiveness and post-treatment platelet reactivity. Thromb Res 115 (2005) 89-94
70. Montalescot G., Sideris G., Meuleman C., et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 48 (2006) 931-938
71. von Beckerath N., Tauberg D., Pogatsa-Murray G., Schomig E., Kastrati A., and Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation 112 (2005) 2946-2950
72. Gurbel P.A., Bliden K.P., Hayes K.M., Yoho J.A., Herzog W.R., and Tantry U.S. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 45 (2005) 1392-1396
73. Kastrati A., vonBeckerath N., Joost A., Pogatsa-Murray G., Gorchakova O., and Schomig A. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 110 (2004) 1916-1919
74. Hochholzer W., Trenk K., Frundi D., et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111 (2005) 2560-2564
75. Patti G., Colonna G., Pasceri V., Pepe L.L., Montinaro A., and DiSciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 111 (2005) 2099-2106
76. Sciascio G. A prospective, double-blind, randomized trial evaluating a 600 mg clopidogrel loading dose prior to PCI in patients on chronic clopidogrel therapy. Presented at: Transcatheter Cardiovascular Therapeutics, October 22, 2007; Washington, DC.
77. Angiolillo D.J., Shoemaker S.B., Desai B., et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115 (2007) 708-716
78. von Beckerath N., Kastrati A., Wieczorek A., et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 28 (2007) 1814-1819
79. Wilkinson G.R. Drug metabolism and variability among patients in drug response. N Engl J Med 352 (2005) 2211-2221
80. Lau W.C., Carville D.G.M., Guyer K.E., Neer C.J., and Bates E.R. St. John's wort enhances the platelet inhibitory effect of clopidogrel "resistant" healthy volunteers. J Am Coll Cardiol 45 (2005) 382 (abstr)
81. Lee S.W., Park S.W., Hong M.K., et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 46 (2005) 1833-1837
82. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am J Cardiol 97 (2006) 38-43
83. Campo G., Valgimigli M., Gemmati D., et al. Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism?. Evidence from a clopidogrel-to-ticlopidine crossover study. J Am Coll Cardiol 50 (2007) 1132-1137
84. Smith S.C., Feldman T.E., Hirshfeld J.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (ACC/AHA/SCAI Writing Committee to update the 2001 guidelines for percutaneous coronary intervention. J Am Coll Cardiol 47 (2006) 216-235
85. Hirsh J., Warkentin T.E., Shaughnessy S.G., et al. Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest 119 Suppl 1 (2001) 64S-94S
86. Coughlin S.R. Thrombin signaling and protease-activated receptors. Nature 407 (2000) 258-264
87. Lincoff A.M., Bittl J.A., Kleiman N.S., et al., REPLACE-1 Investigators. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 Trial). Am J Cardiol 93 (2004) 1092-1096
88. Lincoff A.M., Bittl J.A., Harrington R.A., et al., REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. JAMA 289 (2003) 853-863
89. Gibson C.M., Buros J.L., Shah S., et al. Association of antiplatelet and antithrombin therapy with ischemia on Holter monitoring following percutaneous coronary intervention (PCI): a PROTECT TIMI 30 analysis. J Am Coll Cardiol 49 Suppl B (2007) 39B (abstr)
90. Gurbel P.A., Bliden K.P., DiChiara J., et al. Bivalirudin with and without eptifibatide for elective stenting: a pharmacodynamic study of platelet reactivity and its relation to periprocedural myocardial infarction. Circulation 116 (2007) II518 (abstr)
91. Wiviott S.D., Michelson A.D., Berger P.D., Lepor N.E., and Kereiakes D.J. Therapeutic goals for effective platelet inhibition: a consensus document. Rev Cardiovasc Med 7 (2006) 214-225
92. Tantry U.S., Bliden K.P., and Gurbel P.A. Prasugrel. Expert Opin Investig Drugs 15 (2006) 1627-1633
93. 12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 29 (2008) 21-30
94. Jakubowski J.A., Matsushima N., Asai F., et al. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol 63 (2007) 421-430
95. Weerakkody G.J., Jakubowski J.A., Brandt J.T., Payne C.D., Naganuma H., and Winters K.J. Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis. J Cardiovasc Pharmacol Ther 12 (2007) 205-212
96. Wiviott S.D., Antman E.M., Winters K.J., et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 111 (2005) 3366-3373
97. Wiviott S.D., Antman E.M., Gibson C.M., et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 152 (2006) 627-635
98. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
99. Wivott S.D., Trenk D., Frelinger A.L., et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention. Circulation 116 (2007) 2923-2932
100. Tantry U.S., Bliden K.P., and Gurbel P.A. AZD6140. Expert Opin Investig Drugs 16 (2007) 225-229
101. Husted S., Emanuelsson H., Heptinstall S., et al. Pharmacodyamics, pharmokinetics, and safety of the oral reversible P2Y12 antogonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 27 (2006) 1038-1047
102. Cannon C.P., Husted S., Harrington R.A., et al. Safety, tolerability and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome-primary results of the DISPERSE 2 trial. J Am Coll Cardiol 50 (2007) 1844-1851
103. Storey R.F., Husted S., Harrington R.A., et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 50 (2007) 1852-1856
104. Storey R.F., Wilcox R.G., and Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets 13 (2002) 407-413
105. Storey R.F., Oldroyd K.G., and Wilcox R.G. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 85 (2001) 401-407
106. Greenbaum A.B., Grines C.L., Bittle J.A., et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 151 (2006) 689 e1-10
107. CHAMPION Trial: Cangrelor versus standard tHerapy to Achieve optimal Management of Platelet InhibitiON. http://www.clinicaltrials.gov/ct/show/NCT00385138?order=1 Accessed October 29, 2007
108. Ahn H.-S., Chackalamannil S., Boykow G., Graziano M.P., and Foster C. Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis, and inflammatory diseases. Curr Pharm Design 9 (2003) 2349-2365
109. Moliterno DJ, Jennings L, Becker RC, et al., on behalf of the TRA-PCI Investigators. Results of a multinational randomized, double-blind, placebo-controlled study of a novel thrombin receptor antagonist SCH 530348 in percutaneous coronary intervention. Presented at: American College of Cardiology Meetings; March 24, 2007; New Orleans, LA.